Leerink Partners Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target of $7.
Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target of $7.